Published on October 8, 2026, in the Journal of Clinical Oncology, the findings offer a path to sharper treatment tailoring for children outside the high-risk category.
Decoding Telomere Biology in Childhood Cancers
Neuroblastomas can regress spontaneously or follow an aggressive and life-threatening course. Clinicians have struggled with stratification within the non-high-risk patient cohort, balancing the hazard of overtreating children with favorable tumors against the danger of undertreating aggressive neuroblastomas. Priv.-Doz. Dr. Carolina Rosswog and Prof. Dr. Matthias Fischer led an experimental pediatric oncology team at the Uniklinik Köln to evaluate the prognostic accuracy of telomere maintenance mechanisms for the risk classification of children with neuroblastoma compared to the current standard of care. Telomere maintenance mechanisms allow tumor cells to multiply indefinitely and are a key feature of many cancer types. The study shows that these biological properties are also significant for clinical risk assessment in children with neuroblastomas. Within the large group of non-high-risk neuroblastomas, a classification based on telomere maintenance mechanisms could reliably distinguish patients with a very favorable disease course from those with an unfavorable one. The prognostic power of this classification was significantly higher than all currently used prognostic markers and classification systems.
Advancing Individualized Pediatric Oncology Protocols
The study, titled “Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma” under DOI 10.1200/JCO-26-00742, establishes a foundation for upcoming clinical trials. Our results show how a better understanding of the biological properties of tumors can be translated into a more precise clinical risk assessment,
stated Dr. Rosswog, the study’s first author, highlighting that the analysis of telomere maintenance mechanisms captures a biological level that is not represented by the risk factors used to date. Building on these results, a national therapeutic trial is currently being prepared in which individual therapy decisions are to be made on the basis of information about the telomere maintenance status of the tumors. Goal is to tailor treatment as precisely as possible to the individual disease risk, improve chances of cure, and at the same time avoid unnecessary treatment toxicity and long-term treatment damage,
added Prof. Fischer.
References
- Rosswog, C., et al. (2026). Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma. Journal of Clinical Oncology. DOI: 10.1200/JCO-26-00742.
Disclaimer: This article is produced for informational and educational purposes by Archyde.com. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified pediatric oncologist or healthcare provider regarding specific medical conditions and clinical trial eligibility.
